FDA-Device2026-01-14Class IIPROCESSING DEFECT

Meridian Bioscience Revogene C. difficile assay recalled for declining performance and false-negative results

OTHERNationwide distributionMedical devices

What this means

Meridian Bioscience's Revogene C. difficile diagnostic test (a lab assay used with the Revogene instrument) may show declining accuracy over time in certain lots. This could produce false-negative results, meaning the test might not detect C. difficile infection when it is present.

  • Stop using affected lots: 410300U195, 410300U196, 410300U197, 410300U201
  • Contact Meridian Bioscience for guidance on replacement or alternative testing
  • Review recent test results from these lots with your lab director or healthcare provider
The agency's original wording
Hazard

The affected lots show a decline in performance over time, which may lead to false-negative results.

Intended for
Adults
Illnesses reported
None reported
Sold states
US Nationwide distribution and the OUS country of Italy.
Affected count
211 units
Manufactured in
3471 River Hills Dr, Cincinnati, OH, United States
Products
Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300

Official notice

https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=Z-1019-2026

Want us to check the next one for you?

We read every CPSC, FDA, USDA, and NHTSA notice and email you a plain-English Sunday brief covering your household — free, no credit card. Or upgrade to as-it-happens alerts for the brands you actually own.

Free · One email a week · Unsubscribe anytime